Prognostic value of decreased FOXP1 protein expression in various tumors: A systematic review and meta-analysis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Xiao, Jian ^a   He, Bixiu ^a   Zou, Yong ^a   Chen, Xi ^a   Lu, Xiaoxiao ^a   Xie, Mingxuan ^a   Li, Wei ^a   He, Shuya ^b   You, Shaojin ^c   Chen, Qiong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; METABOLISM; NEOPLASM; PATHOLOGY; PROGNOSIS; PUBLISHING; TUMOR RECURRENCE;

DISEASE-FREE SURVIVAL; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROGNOSIS; PUBLICATION BIAS; REPRESSOR PROTEINS;

EID: 84979732778     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30437     Document Type: Article

References (46)

1. Shu, W., Yang, H., Zhang, L., Lu, M. M., Morrisey, E. E. Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. J Biol Chem 276, 27488-27497 (2001).
2. Katoh, M., Katoh, M. Human FOX gene family (Review). Int J Oncol 25, 1495-1500 (2004).
3. Jepsen, K., Gleiberman, A. S., Shi, C., Simon, D. I., Rosenfeld, M. G. Cooperative regulation in development by SMRT and FOXP1. Genes Dev 22, 740-745 (2008).
4. Li, S. et al. Foxp1/4 control epithelial cell fate during lung development and regeneration through regulation of anterior gradient 2. Development 139, 2500-2509 (2012).
5. Shu, W. et al. Foxp2 and Foxp1 cooperatively regulate lung and esophagus development. Development 134, 1991-2000 (2007).
6. Li, X. et al. Foxp1 regulates cortical radial migration and neuronal morphogenesis in developing cerebral cortex. PLoS One 10, e0127671 (2015).
7. Zhao, J. et al. Foxp1 Regulates the Proliferation of Hair Follicle Stem Cells in Response to Oxidative Stress during Hair Cycling. PLoS One 10, e0131674 (2015).
8. Cesario, J. M., Almaidhan, A. A., Jeong, J. Expression of forkhead box transcription factor genes Foxp1 and Foxp2 during jaw development. Gene Expr Patterns (2016).
9. Brown, P. J. et al. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. Leukemia 30, 605-616 (2016).
10. Flori, M. et al. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. Blood 127, 1438-1448 (2016).
11. Ackermann, S. et al. FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma. BMC Cancer 14, 840 (2014).
12. Takayama, K. et al. Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. Mol Endocrinol 28, 2012-2024 (2014).
13. Yu, B. et al. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma. Ann Hematol 90, 701-708 (2011).
14. He, M. et al. Prognostic significance of miR-34a and its target proteins of FOXP1, p53, and BCL2 in gastric MALT lymphoma and DLBCL. Gastric Cancer 17, 431-441 (2014).
15. Barrans, S. L., Fenton, J. A., Banham, A., Owen, R. G., Jack, A. S. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104, 2933-2935 (2004).
16. Rayoo, M. et al. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers. J Clin Pathol 62, 896-902 (2009).
17. Giatromanolaki, A. et al. Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression. Mod Pathol 19, 9-16 (2006).
18. Feng, J. et al. High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol 138, 230-235 (2012).
19. Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6, e1000100 (2009).
20. Nyman, H. et al. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. Eur J Haematol 82, 364-372 (2009).
21. Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008-2012 (2000).
22. Zhou, L. et al. Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis. Sci Rep 5, 12733 (2015).
23. Krieg, A., Riemer, J. C., Telan, L. A., Gabbert, H. E., Knoefel, W. T. CXCR4-A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis. PLoS One 10, e0130192 (2015).
24. Banham, A. H. et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11, 1065-1072 (2005).
25. Sagaert, X. et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 24, 2490-2497 (2006).
26. Hoeller, S., Schneider, A., Haralambieva, E., Dirnhofer, S., Tzankov, A. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1. Histopathology 57, 73-80 (2010).
27. Hu, C. R., Wang, J. H., Wang, R., Sun, Q., Chen, L. B. Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China. Acta Histochem 115, 137-143 (2013).
28. Wong, K. K. et al. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOPtreated diffuse large B-cell lymphoma patients. Leukemia 28, 362-372 (2014).
29. Tzankov, A. et al. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. J Hematol Oncol 8, 70 (2015).
30. Fox, S. B. et al. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res 10, 3521-3527 (2004).
31. Ijichi, N. et al. Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Horm Cancer 3, 147-159 (2012).
32. Han, S. L. et al. FOXP1 expression predicts polymorphic histology and poor prognosis in gastric mucosa-associated lymphoid tissue lymphomas. Dig Surg 26, 156-162 (2009).
33. Zhai, L. et al. Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type. Tumour Biol 32, 913-920 (2011).
34. Jiang, W. et al. Expression of FOXP1 in mucosa-associated lymphoid tissue lymphoma suggests a large tumor cell transformation and predicts a poorer prognosis in the positive thyroid patients. Med Oncol 29, 3352-3359 (2012).
35. Zhang, Y. et al. Prognostic significance of FOXP1 as an oncogene in hepatocellular carcinoma. J Clin Pathol 65, 528-533 (2012).
36. De Smedt, L. et al. Expression of FOXP1 and Colorectal Cancer Prognosis. Lab Med 46, 299-311 (2015).
37. Hu, Z. et al. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis. Tumour Biol 36, 7269-7275 (2015).
38. Walker, M. P. et al. FOXP1 potentiates Wnt/beta-catenin signaling in diffuse large B cell lymphoma. Sci Signal 8, 12 (2015).
39. Takayama, K. et al. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochem Biophys Res Commun 374, 388-393 (2008).
40. Choi, E. J. et al. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. Oncotarget 7, 3506-3519 (2016).
41. Mraz, M. et al. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood 124, 84-95 (2014).
42. van Boxtel, R. et al. FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis. Cell Death Differ 20, 1219-1229 (2013).
43. Li, J. et al. Prognostic Value of Ezrin in Various Cancers: A Systematic Review and Updated Meta-analysis. Sci Rep 5, 17903 (2015).
44. Qi, X. W. et al. Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep 5, 8924 (2015).
45. Zhang, J. et al. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep 5, 9800 (2015).
46. Wu, P. et al. Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis. Oncotarget (2016).